Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood

Li, Jiahe; Sharkey, Charles C.; Huang, Danyang; King, Michael R.

doi:10.1007/s12195-015-0378-7

Cited by 8 publications

(9 citation statements)

References 162 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, innovative imaging technologies should be developed to determine the effects of hypothetical CSC-targeting drugs, since tumor shrinkage cannot be considered a measure for their efficacy. Finally, the development of nanoparticles and nanoformulations to be used for CTCs neutralization is an innovative, appealing tool [44].…”

Section: Five-year Viewmentioning

confidence: 99%

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

Gazzaniga

Raimondi

Nicolazzo

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which represents a precious source of biological material derived from both primary and metastatic tumors, has been named a 'liquid biopsy'. While the circulating tumor DNA might be more representative of the bulk of the metastatic tumor, CTCs are thought to reflect more of the metastases-initiating cells. Consequently, a liquid biopsy made of tumor cells and tumor DNA that is able to track cancer evolution, as a fingerprint of the patient's individual tumor, and is easy to perform at every stage of the disease course, sounds attractive. This article mainly focuses on the applications of CTCs to track tumor dynamics in real time using colorectal cancer as a model system. The analysis of viable CTCs at DNA, RNA and protein levels, as well as their expansion in vitro, may allow deep investigation of the features of metastases-initiating cells.

show abstract

Section: Five-year Viewmentioning

confidence: 99%

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

Gazzaniga

Raimondi

Nicolazzo

et al. 2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…Although it has been proven to be a key paradigm for existing nano-medicines, the EPR effect, however, may not be readily translated to the targeting of CTCs in circulation. The physical environment surrounding CTCs is different from that of solid tumors [5]. In solid tumors, high interstitial fluid pressure represents a major barrier to the delivery of nano-medicine caused by enhanced stiffness of extracellular matrices and leaky tumor-associated vasculature [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles

et al. 2016

Self Cite

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are responsible for metastases in distant organs via hematogenous dissemination. Fundamental studies in the past decade have suggested that neutralization of CTCs in circulation could represent an effective strategy to prevent metastasis. Current paradigms of targeted drug delivery into a solid tumor largely fall into two main categories: unique cancer markers (e.g. overexpression of surface receptors) and tumor-specific microenvironment (e.g. low pH, hypoxia, etc.). While relying on a surface receptor to target CTCs can be greatly challenged by cancer heterogeneity, targeting of tumor microenvironments has the advantage of recognizing a broader spectrum of cancer cells regardless of genetic differences or tumor types. The blood circulation, however, where CTCs transit through, lacks the same tumor microenvironment as that found in a solid tumor. In this study, a unique “microenvironment” was confirmed upon introduction of cancer cells of different types into circulation where activated platelets and fibrin were physically associated with blood-borne cancer cells. Inspired by this observation, synthetic silica particles were functionalized with activated platelet membrane along with surface conjugation of tumor-specific apoptosis-inducing ligand cytokine, TRAIL. Biomimetic synthetic particles incorporated into CTC-associated micro-thrombi in lung vasculature and dramatically decreased lung metastases in a mouse breast cancer metastasis model. Our results demonstrate a “Trojan Horse” strategy of neutralizing CTCs to attenuate metastasis.

show abstract

“…8 Finally, most conventional cancer therapeutics have a relatively short half-life and poor permeability, which may influence curative effect. 9 Therefore, it is urgent to develop a novel systemic chemotherapy for HCC in medicine.…”

Section: Introductionmentioning

confidence: 99%

Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis

Guo

Lin

et al. 2016

IJN

View full text Add to dashboard Cite

Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood

Cited by 8 publications

References 162 publications

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells

Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles

Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis

Contact Info

Product

Resources

About